Bivalirudin foR Acute Myocardial Infarction underGoing Angioplasty in CHinese patienTs. (BRIGHT)
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Received Date ICMJE | August 22, 2012 | ||||
| Last Updated Date | April 8, 2013 | ||||
| Start Date ICMJE | Not Provided | ||||
| Primary Completion Date | Not Provided | ||||
| Current Primary Outcome Measures ICMJE | Not Provided | ||||
| Original Primary Outcome Measures ICMJE | Not Provided | ||||
| Change History | Complete list of historical versions of study NCT01696110 on ClinicalTrials.gov Archive Site | ||||
| Current Secondary Outcome Measures ICMJE | Not Provided | ||||
| Original Secondary Outcome Measures ICMJE | Not Provided | ||||
| Current Other Outcome Measures ICMJE | Not Provided | ||||
| Original Other Outcome Measures ICMJE | Not Provided | ||||
| Descriptive Information | |||||
| Brief Title ICMJE | Bivalirudin foR Acute Myocardial Infarction underGoing Angioplasty in CHinese patienTs. | ||||
| Official Title ICMJE | Bivalirudin for Acute Myocardial Infarction Undergoing Angioplasty in Chinese Patients: a Randomized, Single-blind, Controlled Trial. | ||||
| Brief Summary | The study would enrolled a total of 2100 AMI patients undergoing PCI to one of three antithrombotic regimens: bivalirudin alone, or unfractionated heparin alone, or unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor. All enrolled patients would be followed-up to 30 days, 6 months, and 1 year. The purpose of the study is to evaluate the efficacy and safety of bivalirudin in AMI patients with DES. |
||||
| Detailed Description | This is a prospective, randomized, single-blind, active drug controlled multicenter clinical research and the study would enrolled a total of 2100 AMI patients undergoing percutaneous coronary intervention (PCI) to one of three antithrombotic regimens: bivalirudin alone, or unfractionated heparin alone, or unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor. All enrolled patients would be followed-up to 30 days, 6 months, and 1 year. The purpose of the study is to evaluate the efficacy and safety of bivalirudin in AMI patients with DES. |
||||
| Study Type ICMJE | Expanded Access | ||||
| Study Phase | Not Provided | ||||
| Study Design ICMJE | Not Provided | ||||
| Condition ICMJE | Acute Myocardial Infarction | ||||
| Intervention ICMJE | Drug: Bivalirudin
Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.
Other Name: Taijianing |
||||
| Study Arm (s) | Not Provided | ||||
| Publications * | Not Provided | ||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
| Recruitment Information | |||||
| Recruitment Status ICMJE | Available | ||||
| Enrollment ICMJE | Not Provided | ||||
| Completion Date | Not Provided | ||||
| Primary Completion Date | Not Provided | ||||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
| Gender | Both | ||||
| Ages | 18 Years to 80 Years | ||||
| Accepts Healthy Volunteers | Not Provided | ||||
| Contacts ICMJE |
|
||||
| Location Countries ICMJE | Not Provided | ||||
| Administrative Information | |||||
| NCT Number ICMJE | NCT01696110 | ||||
| Other Study ID Numbers ICMJE | SYNH20120001, 2011BAI11B07 | ||||
| Has Data Monitoring Committee | Not Provided | ||||
| Responsible Party | Han Yaling, Shenyang Northern Hospital | ||||
| Study Sponsor ICMJE | Shenyang Northern Hospital | ||||
| Collaborators ICMJE |
|
||||
| Investigators ICMJE | Not Provided | ||||
| Information Provided By | Shenyang Northern Hospital | ||||
| Verification Date | April 2013 | ||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||